Andrew Anderson shares his insights about working from home, his non-work coping mechanisms, and how ACD/Labs is building collaborative software interfaces to support continued work from home requirements for analytical chemists.
Andrew Anderson provides his insights on why digitalization and data on the cloud go hand-in-hand in this blog article.
Andrew Anderson shares his experiences helping customers identify and articulate gaps in their process, and how software can help fill those gaps.
Andrew Anderson shares some guidelines on how our software can support scientists shifting to a remote working environment.
What will the Lab of the Future look like? Andrew Anderson offers his insights into how ACD/Labs is poised to deliver products and capabilities to help usher companies into this unknown future.
For scientists involved in pharmaceutical development, high throughput experimentation is commonplace for activities such as reaction optimization, process development, catalyst screening, and reaction scale-up. While there are many observed benefits of implementing HTE workflows in laboratories, it also dramatically affects corporate informatics infrastructures and there are significant impediments to its utilization. In order to optimize laboratory efficiency and support the lab of the future, the industry requires a technological solution that can help streamline workflows and demonstrate data integrity. That's why we've recently launched Katalyst D2D to solve the industry’s greatest pain points in HT experimentation. Read on to learn more about our new solution for high throughput experimentation and parallel synthesis.
Andrew Anderson muses about our upcoming visit to our 23rd Pittcon conference as we celebrate our 25th anniversary with an exciting new product launch.
In pharma, drug substances (and the resulting formulated drug products) must conform to a variety of quality specifications in order to be approved for use by healthcare practitioners and patients. While most of us who have worked in pharma know the various regulatory statutes and advisory guidance (and can quote them chapter and verse!), my belief is that there is a challenge in the practical and efficient implementation of quality practices that support conformance. When considering the increasing ‘fracturing’ of supply chains that support demand for drug substances in both clinical and healthcare systems worldwide, this challenge only continues to grow.
Andrew Anderson reports on the 2017 AAPS Annual Conference by taking a closer look at his recent byline in Laboratory Equipment. He also introduces Joe DiMartino, ACD/Labs' newly appointed solution manager for Luminata, and previews Joe's recent Q&A with Outsourcing-Pharma.com, which discusses how QbD and impurity control management directly impact process development within pharmaceutical R&D organizations.
PITTCON 2017 was a particularly big event for the ACD/Labs team this year because we were focused on the launch of Luminata, our new informatics solution for comprehensive impurity and characterization management. The five days we spent in Chicago were the culmination of months of hard work across the entire organization, and I’m pleased to say that the launch went off without a hitch. I had the opportunity to meet with the folks at LabTube to talk about ACD/Labs and our vision for Luminata. Watch the video in our post.